Key facts
- This page summarizes David E. Lazar's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2025, 16:48.
David E. Lazar - 26 Feb 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Reporting relationship
- Interim CEO, 10%+ Owner
- Issuer ticker
- CYCC
- Reported as of
- 26 Feb 2025
- Net transaction value
- -$5,507,996
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2025, 16:48:15 UTC
- Prior SEC filing
- 10 Mar 2025
- Next SEC filing
- 07 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David E. Lazar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Lazar filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 28 Feb 2025.
Change
- Previous filing in this sequence was filed on 10 Mar 2025.
- Current net transaction value: -$5,507,996.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,650,000
- Change %
- Price
- Shares after
- 2,650,000
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
CYCC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +191,978,820
- Change %
- +7244%
- Price
- Shares after
- 194,628,820
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F3, F4
CYCC
transaction
Common Stock
Sale
- Transaction value
- $5,507,996
- Shares
- -194,628,820
- Change %
- -100%
- Price
- $0.0283*
- Shares after
- 0
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCC
transaction
Derivative
Series C Convertible Preferred Stock
Options Exercise
- Transaction value
- Shares
- -1,000,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,650,000
- Exercise price
- Footnotes
- F2, F6, F7
CYCC
transaction
Derivative
Series D Convertible Preferred Stock
Options Exercise
- Transaction value
- Shares
- -1,745,262
- Change %
- -83%
- Price
- Shares after
- 354,738
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 191,978,820
- Exercise price
- Footnotes
- F4, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
These shares represent the conversion of 1,000,000 shares of the Series C Convertible Preferred Stock (the "Series C Preferred Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") owned by the Reporting Person into shares of the Company's common stock, par value $0.001 per share (the "Common Stock").
Footnote F2
The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
Footnote F3
These shares represent the conversion of 1,745,262 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock") owned by the Reporting Person into shares of Common Stock of the Company.
Footnote F4
The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
Footnote F5
On February 26, 2025, the Reporting Person sold 194,628,820 shares of Common Stock in a private transaction for total consideration of $5,500,000.
Footnote F6
The Series C Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
Footnote F7
At a closing on January 6, 2025, the Reporting Person acquired 1,000,000 shares of Series C Preferred Stock from the Company for a total purchase price of $1,000,000. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time.
Footnote F8
The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
Footnote F9
At a closing on February 6, 2025, the Reporting Person acquired 2,100,000 shares of Series D Preferred Stock from the Company for a total purchase price of $2,100,000. Each share of Series D Preferred Stock is convertible into 110 shares of the Company's Common Stock at any time.